Current concepts in the pathophysiology of glaucoma

Indian Journal of Ophthalmology

Volumn 57, Issue 4, 2009, Pages 257-266

  Agarwal, Renu ^a   Gupta, Suresh K ^a   Agarwal, Puneet ^a   Saxena, Rohit ^b   Agrawal, Shyam ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Glaucoma; Pathophysiology; Retinal ganglion cells

Indexed keywords

GLUTAMIC ACID;

APOPTOSIS; EYE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; ISCHEMIA; METABOLISM; PATHOPHYSIOLOGY; RETINA GANGLION CELL; REVIEW; VASCULARIZATION;

APOPTOSIS; EYE; GLAUCOMA; GLUTAMIC ACID; HUMANS; ISCHEMIA; OCULAR HYPERTENSION; RETINAL GANGLION CELLS;

EID: 68249138220     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.53049     Document Type: Review

References (134)

1. Gupta N, Weinreb RN. New definitions of glaucoma. Curr Opin Ophthalmol 1997;8:38-41.
2. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999;18:39-57.
3. Airaksinen PJ, Alanko HI. Effect of retinal nerve fibre loss on the optic nerve head configuration in early glaucoma. Graefes Arch Clin Exp Ophthalmol 1982;220:193-6.
4. Quigley HA, Dunkelbarger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 1989;107:453-64.
5. Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med 2003;49:90-5.
6. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995;36:774-86.
7. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000;41:764-74.
8. Levin, LA. Mechanisms of optic neuropathy. Curr Opin Ophthalmol 1997;78:9-15.
9. Farkas RH, Grosskreutz CL. Apoptosis, neuroprotection and retinal ganglion cell death: An overview. Int Ophthalmol Clin 2001;41: 111-30.
10. Quigley HA, Dunkelberger G, Green W. Chronic human glaucoma causing selectively greater loss of large optic nerve fibres. Ophthalmology 1998;95:357-63.
11. Glovinsky Y, Quigley H, Dunkelburger G. Retinal ganglion cell loss is size dependent in experimental glaucoma. Invest Ophthalmol Vis Sci 1991;32:184-91.
12. Glovinsky Y, Quigley H, Pease M. Foveal ganglion cell loss is size dependent in experimental glaucoma. Invest Ophthalmol Vis Sci 1993;34:395-400.
13. James EM, Hideya U, Joseph C. Retinal ganglion cell death in experimental glaucoma. Br J Ophthalmol 2000;84:303-10.
14. Bien A, Seidenbecher CI, Bockers TM, Sabel BA, Kreutz MR. Apoptotic versus necrotic characteristics of retinal ganglion cell death after partial optic nerve injury. J Neurotrauma 1999;16:153-63.
15. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
16. Marc BG, Declan P M, Colm JO, Thomas GC. Retinal ganglion cells: Dying to survive. Int J Dev Biol 2006;50:665-74.
17. Kermer P, Klöcker N, Labes M, Bähr M. Inhibition of CPP32-like proteases rescues axotomized retinal ganglion cells from secondary cell death in vivo. J Neurosci 1998;18:4656-62.
18. Spalding KL, Dharmarajan AM, Harvey AR. Caspase independent retinal ganglion cell death after target ablation in the neonatal rat. Eur J Neurosci 2005;21:33-45.
19. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, et al. Prevalence of glaucoma: The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504.
20. Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, et al. A population-based evaluation of glaucoma screening: The Baltimore Eye Survey. Am J Epidemiol 1991;134:1102-10.
21. Hendrickx KH, van den Enden A, Rasker MT, Hoyng PF. Cumulative incidence of patients with disc hemorrhages in glaucoma and the effect of therapy. Ophthalmology 1994;101:1165-72.
22. Clark AF, Miggans ST, Wilson K, Browder S, McCartney MD. Cytoskeletal changes in cultured human glaucoma trabecular meshwork cells. J Glaucoma 1995;4:183-8.
23. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984;91:564-79.
24. Grierson I. What is open angle glaucoma Eye 1987;l:15-28.
25. Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of 'plaque material' in the inner-and outer wall of Schlemm's canal in normal-and glaucomatous eyes. Exp Eye Res 1986;42:443-55.
26. Knepper PA, Goossens W, Hvizd M, Palmberg PF. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1986;37:1360-7.
27. Lutjen-Drecoll E, Rohen JW. Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas. St. Louis: Mosby Year; 1996. p. 89-123.
28. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK. Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res 1997;64:85-96.
29. Chauhan BC, Pan J, Archibald ML, LeVatte TL, Kelly ME, Tremblay F. Effect of intraocular pressure on optic disc topography, electroretinography, and axonal loss in a chronic pressure-induced rat model of optic nerve damage. Invest Ophthalmol Vis Sci 2002;43:2969-76.
30. Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci 2002;43:402-10.
31. Mittag TW, Danias J, Pohorenec G, Yuan HM, Burakgazi E, Redman RC, et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2000;41:3451-9.
32. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laserinduced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-55.
33. Naskar R, Wissing M, Thanos S. Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model of glaucoma. Invest Ophthalmol Vis Sci 2002;43:2962-8.
34. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995;61:33-44.
35. Agar A, Yip SS, Hill MA, Coroneo MT. Pressure related apoptosis in neuronal cell lines. J Neurosci Res 2000;60:495-503.
36. Johnson EC, Morrison JC, Farrell S, Deppmeier L, Moore CG, McGinty MR. The effect of chronically elevated intraocular pressure on the rat optic nerve head extracellular matrix. Exp Eye Res 1996;62:663-74.
37. Pena JD, Taylor AW, Ricard CS, Vidal I, Hernandez MR. Transforming growth factor beta isoforms in human optic nerve heads. Br J Ophthalmol 1999;83:209-18.
38. Cordeiro MF. Beyond mitomycin: TGF-beta and wound healing. Prog Retin Eye Res 2002;21:75-89
39. Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997;91:439-42.
40. Li G, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 2005;46:175-82.
41. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-anoikis". Apoptosis 2002;7:247-60.
42. Zhang X, Cheng M, Chintala SK. Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration. Invest Ophthalmol Vis Sci 2004;45:2374-83.
43. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 2000;118:666-73.
44. Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia 2001;33:205-16.
45. Nickells W. Retinal ganglion cell death in glaucoma: The how, the witty and the maybe. J Glaucoma 1996;5:345-56.
46. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, et al. Tumor necrosis factor-mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006;26:12633-41.
47. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: A potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 2000;32:42-50.
48. Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Torri V, Liberati A. Randomized clinical trials on medical treatment of glaucoma: Are they appropriate to guide clinical practice Arch Ophthalmol 1993;111:96-103.
49. Chauhan BC. The relationship between intraocular pressure and visual field progression in glaucoma. In: Drance SM, editor. Update to glaucoma, blood flow and drug treatment. Amsterdam: Kugler 1995. p. 1-6.
50. Wang JJ, Mitchell P, Smith W. Is there an association between migraine headache and open-angle glaucoma Findings of the Blue Mountains Study. Ophthalmol 1997;104:1714-9.
51. Curseifen C, Wisse M, Curseifen S, Junemann A, Martus P, Korth M. Migraine and tension headache in high-pressure and normal-pressure glaucoma. Am J Ophthalmol 2000;129:102-4.
52. Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol 1997;235:634-8.
53. O'Brien C, Butt Z. Blood flow velocity in the peripheral circulation of glaucoma patients. Ophthalmologica 1999;213:150-3.
54. Cellini M, Possati GL, Profazio V, Sbrocca M, Caramazza N, Caramazza R. Color Doppler imaging and plasma levels of endothelin-1 in low-tension glaucoma. Acta Ophthalmol Scand 1997;224:11-3.
55. Noske W, Hensen J, Wiederholt M. Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch Clin Exp Ophthalmol 1997;235:551-2.
56. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma 1997;6:83-9.
57. Hollo G, Lakatos P, Farkas K. Cold pressor test and plasma endothelin-1 concentration in primary open-angle and capsular glaucoma. J Glaucoma 1998;7:105-10.
58. Stroman GA, Stewart WC, Golnik KC, Cure JK, Olinger RE. Magnetic resonance imaging in patients with low-tension glaucoma. Arch Ophthalmol 1995;113:168-72.
59. Ong K, Farinelli A, Billson F, Houang M, Stern M. Comparative study of brain magnetic resonance imaging findings in patients with low-tension glaucoma and control subjects. Ophthalmol 1995;102:1632-8.
60. Nomura H, Shimokata H, Ando F, Miyake Y, Kuzuya F. Age-related changes in intraocular pressure in a large Japanese population: A cross-sectional and longitudinal study. Ophthalmology 1999;106:2016-22.
61. Harris A, Arend O, Chung HS, Kagemann L, Cantor L, Martin B. A comparative study of betaxolol and dorzolamide on the ocular circulation in normal-tension glaucoma patients. Ophthalmology 2000;107:430-4.
62. Bill A, Sperber GO. Control of retinal and choroidal blood flow. Eye 1990;4:319-25.
63. Matsuura K, Kawai Y. Effects of hypothermia and aging on postischemic reperfusion in rat eyes. Jpn J Physiol 1998;48:9-15.
64. Michelson G, Langhans M J, Harazny J, Dichtl A. Visual field defect and perfusion of the juxtapapillary retina and the neuroretinal rim area in primary open-angle glaucoma. Graefe's Arch Clin Exp Ophthalmol 1998;236:80-5.
65. Chung HS, Harris A, Kagemann L, Martin B. Peripapillary retinal blood flow in normal-tension glaucoma. Br J Ophthalmol 1999;83:466-9.
66. Grunwald JE, Piltz J, Hariprasad SM, Dupont J, Maguire MG. Optic nerve blood flow in glaucoma: Effect of systemic hypertension. Am J Ophthalmol 1999;127:516-22.
67. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: The Egna-Neumarkt Study. Ophthalmology 2000;107:1287-93.
68. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haeflinger IO, Flammer J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res 2000;21:867-76.
69. Golubnitschaja O, Yeghiazaryan, Kristina RN, Liu R, Mönkemann H, Leppert D, et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma 2004;13:66-72.
70. Neal MJ, Cunningham JR, Hutson PH, Hogg J. Effects of ischaemia on neurotransmitter release from the isolated retina. J Neurochem 1994;62:1025-33.
71. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Am Med Assoc Arch Ophthalmol 1957;58:193-201.
72. Olney JW. Glutamate-induced retinal degeneration in neonatal mice: Electron microscopy of the acutely evolving lesion. J Neuropathol Exp Neurol 1969;28:455-74.
73. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells: Toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996;37:1618-24.
74. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-79.
75. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988;451:205-12.
76. ++ influx elicited by glutamate: Role in neuronal death. Mol Pharmacol 1989;36:106-12.
77. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vis Res 1997;27:3483-93.
78. Li Guo, Salt TE, Maass A, Luong VY, Moss SE, Fred WF, Cordeiro MF. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 2006;47:626-33.
79. Kumada M, Niwa M, Hara A, Matsuno H, Mori H, Ueshima S, et al. Tissue type plasminogen activator facilitates NMDA-receptormediated retinal apoptosis through an independent fibrinolytic cascade. Invest Ophthalmol Vis Sci 2005;46:1504-7.
80. Mali RS, Mali, Cheng M, Chintala SK. Plasminogen activators promote excitotoxicity-induced retinal damage. FASEB J 2005;19:1280-9.
81. Montoliu C, Llansola M, Cucarella C, Grisolía S, Felipo V. Activation of the metabotropic glutamate receptor mglur5 prevents glutamate toxicity in primary cultures of cerebellar neurons. Pharmacol Exp Ther 1997;281:643-7.
82. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998;39:972-81.
83. Nicholls D, Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci 1990;11:462-8.
84. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders Trends Neurosci 1996;19:267-71.
85. Moreno MC, Moreno, Sande P, Aldana H, Marcos, Zavalía N de, et al. Effect of glaucoma on the retinal glutamate/glutamine cycle activity. FASEB J 2005;19:1161-2.
86. Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis sci 2000;41:1940-4.
87. Robert KP, Sullivan, Elizabeth WM, Lauren M, Guadalupe R, David VP. Evoked expression of the glutamate transporter GLT-1c in retinal ganglion cells in human glaucoma and in a rat model. Invest Ophthalmol Vis Sci 2006;47:3853-9.
88. Christian M, Thomas P, Martina P, Knut D, Wolfgang BB, Christian KV. Changes of retinal glutamate transporter GLT-1 mRNA levels following optic nerve damage. Mol Vis 2003;9:10-13.
89. Shen W, Slaugter MM. A non excitatory paradigm of glutamate toxicity. J Neurophysiol 2002;87:1629-34.
90. Dkhissi O, Chanut E, Wasowicz M, Savoldelli M, Nguyen-Legros J, Minvielle F, et al. Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Invest Ophthalmol Vis Sci 1999;40:990-5.
91. Kim TW, Kang KB, Choung HK, Park KH, Kim DM. Elevated glutamate levels in the vitreous body of an in vivo model of optic nerve ischemia. Arch Ophthalmol 2000;118:533-6.
92. Wakabayashi Y, Yagihashi T, Kezuka J, Muramatsu D, Usui M, Iwasaki T. Glutamate levels in aqueous humor of patients with retinal artery occlusion. Retina 2006;26:432-6.
93. Dreyer EB, Zurakowski D, Schumer RA, Podos SM Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch ophthalmol 1996;114:299-305.
94. rd, Feldman R, Shen FF, et al. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci 2002;43:2633-7.
95. Hare WA, WoldeMussie E, Lai RK, Ton H, Ruiz G, Chun T, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci 2004;45:2625-39.
96. Honkanen RA, Baruah S, Zimmerman MB, Khanna CL, Weaver YK, Narkiewicz J, et al. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol 2003;121:183-8.
97. Dalton R. Private investigations. Nature 2001;411:129-30.
98. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
99. Neufeld AH. Nitric oxide a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol 1999;43:S129-35.
100. Liu J, Zhao ML, Brosnan CF, Lee SC. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: Role of IL-lbeta and IL-1 receptor antagonist. J Immunol 1996;157:3569-76.
101. Liu B, Neufeld AH. Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch Ophthalmol 2001;119:240-5.
102. Liu B, Neufeld AH. Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia 2000;30:178-86.
103. Yuan L, Neufeld AH. Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 2001;64:523-32.
104. Tsai DC, Hsu WM, Chou CK, Chen SJ, Peng CH, Chi CW, et al. Significant variation of the elevated nitric oxide levels in aqueous humor from patients with different types of glaucoma. Ophthalmologica 2003;216:346-50.
105. Motallebipaur M, Rada-Iqlesias A, Jansson, Wadelius C. The promoter of inducible nitric oxide synthase implicated in glaucoma based on genetic analysis and nuclear factor binding. Mol Vis 2005;11:950-7.
106. Siu AW, Leung MC, Ho TC, Siu FK, Ji JZ, Fai SK. Total retinal nitric oxide production is increased in intraocular pressure-elevated rats. Exp Eye Res 2002;75:401-6.
107. Nathanson JA, Mckee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 1995;36:1774-84.
108. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004;62:455-9.
109. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Ann Rev Physiol 1995;57:683-706.
110. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitrosocompounds. Nature 1993;364:626-32.
111. Hanashima, Namiki H. Reduced viability of vascular endothelial cells by high concentration of ascorbic acid in vitreous humor. Cell Biol Int 1999;23:287-98.
112. Brubaker RF, Bourne WM, Bachman LA, McLaren JW. Ascorbic acid content of human corneal epithelium. Invest Ophthalmol Vis Sci 2000;41:1681-3.
113. Dreyer R, Rose RC. Lachrymal gland uptake and metabolism of ascorbic acid. Proc Soc Exp Biol Med 1993;202:212-6.
114. Ringvold A, Anderssen E, Kjonniksen I. Distribution of ascorbate in the anterior bovine eye. Invest Ophthalmol Vis Sci 2000;41:20-3.
115. 2 in aqueous humor. Exp Eye Res 1984;38:87-93.
116. Truscott RJ. Age-related nuclear cataract oxidation is the key. Exp Eye Res 2005;80:709-25.
117. Yildirim O, Ates, Tamer L, Muslu N, Ercan B, Atik U, et al. Changes in antioxidant enzyme activity and malondialdehyde level in patients with age-related macular degeneration. Ophthalmologica 2004;218:202-6.
118. Chen JZ, Kadlubar FF. A new clue to glaucoma pathogenesis. Am J Med 2003;114:697-8.
119. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004;137:62-9.
120. Yang J, Tezel G, Patil RV, Romno C, Wax MB. Serum autoantibody against glutathione-S-transferase in patients with glaucoma. Invest Ophthalmol Vis Sci 2001;42:1273-6.
121. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2005;46: 877-83.
122. Yildirim O, Ates NA, Ercan B, Muslu N, Unlu A, Tamer L, Atik U, Kanik A. Role of oxidative stress enzymes in open angle glaucoma. Eye 2005;19:580-3.
123. Flammer J, Haefliger IO, Orgul S, Resink T. Vascular dysregulation: A principal risk factor for glaucoma damage. J Glaucoma 1999;8:212-9.
124. Tamm ER, Russell P, Johnson DH, Piatigorsky J. Human and monkey trabecular meshwork accumulate alpha B-crystallin in response to heat shock and oxidative stress. Invest Ophthalmol Vis Sci 1996;37:2402-13.
125. Wiederholt M. Nitric Oxide and endothelin in aqueous humor outflow regulation. In: Haefliger IO, Flammer J. editors. Nitric Oxide and Endothelin in the Pathogenesis of Glaucoma. New York: Lippincott-Raven; 1998. p. 168-77.
126. Orgul S, Gugleta K, Flammer J. Physiology of perfusion as it relates to the optic nerve head. Surv Ophthalmol 1999;43:17-26.
127. Lipton SA. Neuronal protection and destruction by NO. Cell Death Diff 1999;6:943-51.
128. Izzotti A, Sacca SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003;114:638-46.
129. Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: The trabecular meshwork. J Cell Physiol 1999;180:182-9.
130. Saccà SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in human trabecular meshwork and its correlation with intraocular pressure and visual field in primary open angle glaucoma. Arch Ophthalmol 2005;123:458-63.
131. Hosseini A, Lattanzio FA, Schellenberg K, Shaeffer J, Samudre SS, Williams PB. Effects of novel free radical scavengers on intraocular pressure and electroretinograms in rat glaucoma models. FASEB J 2006;20:689.
132. Ko ML, Hu DN, Ritch R, Sharma SC. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci 2000;41: 2967-71.
133. Koseki Y, Kitano S, Podos SM. A nitric oxide synthase inhibitor protects against anoxia in cultured rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1994;35:1968.
134. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 2004;6:S61-74.